ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1222

Association of Fibromyalgia, PTSD and Combat Deployments in Active Duty Military

James Dizmang1 and Jeanne Tofferi2, 1US Air Force, Vacaville, CA, 2US Army, Ft Sam Houston, TX

Meeting: ACR Convergence 2022

Keywords: fibromyalgia, population studies, risk factors

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Fibromyalgia and Other Clinical Pain Syndromes Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Many combat veterans experience unexplained symptoms with long-term disability including chronic pain, irritability, headaches, fatigue, behavioral health conditions, and memory difficulty. These invisible wounds were poorly described when the term “shell shock” was first used in WWI. Half a century later, Gulf War syndrome encompassed many characteristic symptoms of fibromyalgia (FMS), irritable bowel syndrome, and chronic fatigue. Following the wars in Iraq and Afghanistan, onset of FMS and post traumatic stress disorder (PTSD) in active duty and veteran populations was extensively studied. Our understanding deepened with improved knowledge of neurobiology and trauma. However, a clear understanding of the risk factors and interplay between these disorders was lacking. As PTSD and chronic pain syndromes often occur in both combat and non-combat veterans, we hypothesized that deployment was not the primary factor. Behavioral health disorders such as PTSD and musculoskeletal pain such as FMS are leading reasons for premature discharge from active duty. Therefore, understanding risk factors for these disorders is necessary to mitigate the impact on military readiness. Our objective is to determine whether deployment history, history of deployment to a combat zone, and history of deployment to a combat zone during times of high casualty rates were associated with development of FMS.

Methods: A total of 2423 active-duty patients were included. FMS was significantly associated with female sex, sleep apnea, depression, anxiety, PTSD, and deployment to a combat zone during times of peak combat casualties (identified as Iraq from 2003-2008, and Afghanistan from 2009-2013). When controlled for dependent variables in multivariate analysis, deployment to a combat zone during times of peak combat casualties remained significantly associated with FMS. Whereas deployment during other time periods was not associated with the development of FMS.

Results: A total of 2423 active duty patients were included. FMS was the most common primary rheumatologic diagnosis (27.8%). FMS was significantly associated with female sex, sleep apnea, depression, anxiety, PTSD, and deployment to a combat zone during times of peak combat casualties (identified as Iraq from 2003-2008, and Afghanistan from 2009-2013). When the eight variables which were significant in the univariate analyses were included in multivariate analysis, deployment to a combat zone during times of peak combat casualties remained significantly associated with FMS.

Conclusion: Deployment to a combat zone during times of peak casualty incidence was independently associated with the presence of FMS. Further, FMS and deployment during times of peak casualty incidence were both independently associated with the presence of PTSD. This suggests a notable association between deployment at a time of high casualties, FMS, and PTSD. It also underscores the risk that combat adds to development of FMS, as deployment to a combat zone at any time was not significantly associated with FMS. These findings emphasize the unique risk that military members encounter in developing FMS, and will aid in improving the design of future trials on FMS in active duty service members.

Supporting image 1


Disclosures: J. Dizmang, None; J. Tofferi, None.

To cite this abstract in AMA style:

Dizmang J, Tofferi J. Association of Fibromyalgia, PTSD and Combat Deployments in Active Duty Military [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/association-of-fibromyalgia-ptsd-and-combat-deployments-in-active-duty-military/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-fibromyalgia-ptsd-and-combat-deployments-in-active-duty-military/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology